High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

Atherosclerosis

Volumn 124, Issue SUPPL., 1996, Pages

  Assmann, Gerd ^a,b   Schulte, Helmut ^a   Von Eckardstein, Arnold ^b   Huang, Yadong ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Zentrallaboratorium   (Germany)

Author keywords

Coronary heart disease (CHD) risk; High density lipoprotein (HDL) cholesterol; PROCAM; Reverse cholesterol transport

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; SUDDEN DEATH;

EID: 0029759109     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05852-2     Document Type: Conference Paper

References (35)

1. NIH Consensus Development Panel on Triglyceride, High Density Lipoprotein, and Coronary Heart Disease, NIH Consensus Conference. Triglyceride, high-density lipoprotein and coronary heart disease. J Am Med Assoc 1993;269:505.
2. Assmann G, Obenvittler W, Schulte H, Schriewer H, Funke H, Epping PH, Hauss WH. Prediction and early diagnosis of coronary disease. Prospective epidemiologic study of industrial workers in Westphalia. Internist 1980;21:446.
3. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499.
4. Assmann G, Schulte H. PROCAM Trial. Hedingen/ Zürich: Panscientia, 1986.
5. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective cardiovascular Münster study. Am J Cardiol 1992;70:733.
6. Nie NH. SPSSX User's Guide. New York: McGraw-Hill, 1983.
7. Ray AA. SAS User's Guide: Basics. Cary, NC: SAS Institute, 1982.
8. Assmann G, Schulte H. Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) study. In: Assmann G (ed.), Lipid Metabolism Disorders and Coronary Heart Disease. Primary Prevention, Diagnosis and Therapy Guidelines for General Practice, 2nd Edn. München: MMV Medizin Verlag, 1993;19-67.
9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707.
10. Jacobs DR (for Lipid Research Clinics Follow-up Study). High density lipoprotein cholesterol and coronary heart disease cardiovascular disease and all-cause mortality. Circulation 1985;72(Suppl III):185.
11. Watkins LO, Neaton JD, Kuller LH. Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the Multiple Risk Factor Intervention Trial. Am J Cardiol 1986;57:538.
12. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977;1:965.
13. Goldbourt U, Medalie JH. High-density lipoprotein cholesterol and incidence of coronary heart disease - the Israeli Ischemic Heart Disease Study. Am J Epidemiol 1979;109:296.
14. Enger SC, Hjermann I, Floss OP, Helgeland A, Holme I, Leren P, Norum KR. High-density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective case-control study in middle-aged men of the Oslo study. Artery 1979;5:170.
15. Shestov CB. Results of four years of follow-up of USSR populations. In: USA-USSR First Lipoprotein Symposium, Bethesda, MD, 1982. US Department of Health and Human Services, National Institutes of Heath, Publication (NIH) 83-1966, pp. 391-407.
16. Keys A, Karvonen MJ, Punsar S, Menotti A, Fidanza F, Farchi G. HDL serum cholesterol and 24-year mortality of men in Finland. Int J Epidemiol 1994;13:428.
17. Pocock SJ, Shaper AG, Philips AN, Walker M, Whitehead TP. High-density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men. Br Med J (Clin Res Ed) 1986;292:515.
18. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237.
19. Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Frick MH. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol 1989;63:42H.
20. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A. Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc 1988;260:641.
21. Huttunen JK, Manninen V, Mänttäri M, Koskinen P, Romo M, Tenkanen L, Heinonen OP, Frick MH. The Helsinki Heart study: central findings and clinical implications. Ann Med 1991;23:155.
22. Eisenberg S. High-density lipoprotein metabolism. J Lipid Res 1984;25:1017.
23. Tall AR. Plasma high-density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379.
24. Assmann G, von Eckardstein A, Funke H. High-density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 1993;87(Suppl III):28.
25. von Eckardstein A, Huang Y, Wu S, Funke H, Noseda G, Assmann G. Uptake, transfer and esterification of cell-derived cholesterol in plasma of patients with familial HDL-deficiency. Atherosclerosis 1994;109:232.
26. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein. Biochemistry 1988;27:25.
27. Huang Y, von Eckardstein A, Assmann G. Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. Arteriosclerosis Thromb 1993;13:445.
28. Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I containing subpopulations. Biochim Biophys Acta 1993;1169:291.
29. von Eckardstein A, Huang Y, Assmann G. Physiological role and clinical relevance of high density lipoprotein subclasses. Curr Opin Lipidol 1994;5:404.
30. Huang Y, von Eckardstein A, Wu S, Maeda N, Assmann G. A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci USA 1994;91:1834.
31. Kawano M, Miida T, Fielding CJ, Fielding PE. Quantitation of pre β-HDL-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid. Biochemistry 1993;32:5025.
32. Assmann G, Huang Y, Wu S, von Eckardstein A. A lipo-protein containing only apo E present in normal and HDL-deficient plasmas releases cholesterol from cells Atherosclerosis 1994;109:334.
33. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1.
34. Ordovas JM, Schaefer EJ. Apolipoprotein E polymorphisms and coronary heart disease risk. Cardiovasc Risk Factors 1994;4:103.
35. Francone OL, Gurakar A, Fielding C. Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for functional unit containing these activities together with apolipoprotein A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem 1989;264:7066.